Prospective, random and control clinical trial of Apatinib associates with concurrent radiotherapy compared with simple radiotherapy in middle and advanced squamous cells esophageal cancer.
Latest Information Update: 03 Jul 2017
Price :
$35 *
At a glance
- Drugs Rivoceranib (Primary)
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 03 Jul 2017 New trial record